Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as doxorubicin, vinblastine, and gemcitabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with newly diagnosed stage I or stage II Hodgkin's lymphoma.


Options:
A: Arm Label: Arm A; Type: OTHER; Interventions: Drug: ABVD | Arm Label: Arm B; Type: OTHER; Interventions: Drug: ABVD and Radiotherapy | Intervention Type: DRUG; Name: ABVD; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: ABVD and Radiotherapy; Assigned to Arm(s): Arm B
B: Arm Label: doxorubicin + vinblastine + gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: doxorubicin hydrochloride, Drug: gemcitabine hydrochloride, Drug: vinblastine, Procedure: fludeoxyglucose F 18 positron-emission tomography (PET) scan, Procedure: CT scan | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine | Intervention Type: DRUG; Name: vinblastine; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine | Intervention Type: PROCEDURE; Name: fludeoxyglucose F 18 positron-emission tomography (PET) scan; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine | Intervention Type: PROCEDURE; Name: CT scan; Assigned to Arm(s): doxorubicin + vinblastine + gemcitabine
C: Arm Label: Favorable - Standard - any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Standard - Any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Intervention Type: DRUG; Name: ABVD q4 weeks; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Standard - Any PET outcome | Intervention Type: DRUG; Name: BEACOPP escalated q3 weeks; Assigned to Arm(s): Favorable - Experimental - PET positive, Unfavorable - Experimental - PET positive | Intervention Type: RADIATION; Name: IN-RT 30 Gy (+ boost 6 Gy residual); Assigned to Arm(s): Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome | Intervention Type: PROCEDURE; Name: FDG-PET scan; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome
D: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine sulfate | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine sulfate | Arm Label: BEACOPP-14 chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisolone, Drug: procarbazine hydrochloride, Drug: vincristine sulfate | Arm Label: BEACOPP-escalated chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisolone, Drug: procarbazine hydrochloride, Drug: vincristine sulfate | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): Arm I, BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: BIOLOGICAL; Name: pegfilgrastim; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I, Arm II, BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: prednisolone; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: vinblastine sulfate; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy

Answer: B